Clinical Study

Uccc-Hem-21-01- A Pilot Study To Assess The Immunological Response Of Covid-19 Vaccine Administered To Patients Receiving Rituximab And Other B Cell Depleting Therapies

Posted Date: May 20, 2021

  • Investigator: Tahir Latif
  • Specialties: Cancer, Oncology
  • Type of Study: Observational/Survey

The goal of this study is to determine the immediate immunological response by measuring antibodies against SARS-CoV-2 spike protein at baseline, 4 and 8 weeks after SARS-CoV-2 vaccine administration in patients who are on active therapy with CD-20 with or without chemotherapy


Patients Must Be Over 18, Willing To And Who Will Be Receiving The Covid-19 Vaccinations, Cd-20 Therapy Group Includes Hematological Malignancy, Autoimmune Or Rheumatological Diagnosis Requiring Current Active Therapy With Cd-20 Antibodies With Or Without Chemotherapy, Or Whose Last Dose Of Cd-20 Therapy Is Within 6 Months Of Planned Covid-19 Vaccine Administration. Control Group Are Patients With Any Malignancy Or Rheumatological Diagnosis Or Autoimmune Diagnosis That Have Never Received C20 Antibodies.


Covid-19, Vaccine, Hematology

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.